Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

• Автори: Viktor Rotbain Curovic (Автор), Morten B. Houlind (Автор), Tine W. Hansen (Автор), Jesper Eugen-Olsen (Автор), Jens Christian Laursen (Автор), Mie K. Eickhoff (Автор), Frederik Persson (Автор), Peter Rossing (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood glucose, while also decreasing risk of kidney disea...